Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation

Pharmacogenetics and Genomics

Volumn 22, Issue 10, 2012, Pages 741-749

  Menon, Saras ^a   Lea, Rod A ^a   Roy, Bishakha ^a   Hanna, Michelle ^a   Wee, Shirley ^a   Haupt, Larisa M ^a   Oliver, Chris ^b   Griffiths, Lyn R ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b Research for Blackmores Limited   (Australia)

Author keywords

gene; migraine; vitamin supplementation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHIONINE SYNTHASE REDUCTASE; PLACEBO; PYRIDOXINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE WITH AURA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

EID: 84866324187     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283576b6b     Document Type: Article

References (38)

1. Dhillon KS, Singh J, Lyall JS. A new horizon into the pathobiology, etiology and treatment of migraine. Med Hypotheses 2011; 77:147-151.
2. Lea R, Colson N, Quinlan S, Macmillan J, Griffiths L. The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet Genomics 2009; 19:422-428.
3. Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, Hennekens CH, Hunter DJ. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 2001; 154:667-672. (Pubitemid 32232164)
4. Parsons AA, Strijbos PJ. The neuronal versus vascular hypothesis of migraine and cortical spreading depression. Curr Opin Pharmacol 2003; 3:73-77. (Pubitemid 36131330)
5. Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997; 120 (Pt 12):2171-2177. (Pubitemid 28014593)
6. Lea RA, Ovcaric M, Sundholm J, MacMillan J, Griffiths LR. The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMC Med 2004; 2:3.
7. Silaste ML, Rantala M, Sampi M, Alfthan G, Aro A, Kesaniemi YA. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J Nutr 2001; 131:2643-2647. (Pubitemid 32947789)
8. Goyette P, Pai A, Milos R, Frosst P, Tran P, Chen Z, et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome 1998; 9:652-656. (Pubitemid 28355328)
9. Goyette P, Sumner JS, Milos R, Duncan AM, Rosenblatt DS, Matthews RG, Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 1994; 7: 195-200. (Pubitemid 24174661)
10. Di Rosa G, Attina S, Spano M, Ingegneri G, Sgro DL, Pustorino G, et al. Efficacy of folic acid in children with migraine, hyperhomocysteinemia and MTHFR polymorphisms. Headache 2007; 47:1342-1344. (Pubitemid 47561535)
11. Kara I, Sazci A, Ergul E, Kaya G, Kilic G. Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res 2003; 111: 84-90. (Pubitemid 36332332)
12. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet 2000; 96: 762-764.
13. Geisel J, Zimbelmann I, Schorr H, Knapp JP, Bodis M, Hubner U, Herrmann W. Genetic defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med 2001; 39:698-704. (Pubitemid 32894413)
14. Ilhan N, Kucuksu M, Kaman D, Ilhan N, Ozbay Y. The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Arch Med Res 2008; 39: 125-130. (Pubitemid 350192019)
15. Rubino E, Ferrero M, Rainero I, Binello E, Vaula G, Pinessi L. Association of the C677T polymorphism in the MTHFR gene with migraine: a metaanalysis. Cephalalgia 2009; 29:818-825.
16. Elmore CL, Wu X, Leclerc D, Watson ED, Bottiglieri T, Krupenko NI, et al. Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Mol Genet Metab 2007; 91:85-97. (Pubitemid 46550928)
17. Gaughan DJ, Kluijtmans LA, Barbaux S, McMaster D, Young IS, Yarnell JW, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001; 157:451-456. (Pubitemid 32710025)
18. Vaughn JD, Bailey LB, Shelnutt KP, Dunwoody KM, Maneval DR, Davis SR, et al. Methionine synthase reductase 66A >G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C->T variant. J Nutr 2004; 134:2985-2990. (Pubitemid 39470073)
19. Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20:765-786. (Pubitemid 32154559)
20. Stewart WF, Lipton RB, Simon D, Liberman J, Von Korff M. Validity of an illness severity measure for headache in a population sample of migraine sufferers. Pain 1999; 79:291-301. (Pubitemid 29076764)
21. Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia 1999; 19:107-114, discussion 74. (Pubitemid 29170106)
22. Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005; 6: 429-440. (Pubitemid 43078769)
23. Rapoport A. New frontiers in headache therapy. Neurol Sci 2011; 32 (Suppl 1):S105-S109.
24. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
25. Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in men. Arch Intern Med 2007; 167:795-801. (Pubitemid 46658337)
26. Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N. Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 1997; 54:362-368. (Pubitemid 27172854)
27. Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alperovitch A. Association between migraine and endothelin type A receptor (ETA-231A/G) gene polymorphism. Neurology 2001; 56:1273-1277. (Pubitemid 32455282)
28. Scher AI, Terwindt GM, Verschuren WM, Kruit MC, Blom HJ, Kowa H, et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol 2006; 59:372-375. (Pubitemid 43202492)
29. Silberstein SD. Shared mechanisms and comorbidities in neurologic and psychiatric disorders. Headache 2001; 41 (Suppl 1):S11-S17.
30. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693-2698. (Pubitemid 23350966)
31. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291:565-575. (Pubitemid 38500310)
32. Homocysteine Lowering Trialists Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316:894-898.
33. Homocysteine Lowering Trialists Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82:806-812.
34. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996; 5:1867-1874. (Pubitemid 26413628)
35. Olteanu H, Munson T, Banerjee R. Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry 2002; 41:13378-13385. (Pubitemid 35303896)
36. Leclerc D,Wilson A, Dumas R, Gafuik C, Song D,Watkins D, et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA 1998; 95:3059-3064. (Pubitemid 28135854)
37. Wilson A, Platt R,Wu Q, Leclerc D, Christensen B, Yang H, et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999; 67:317-323. (Pubitemid 29406795)
38. Woodside JV, Yarnell JW, McMaster D, Young IS, Harmon DL, McCrum EE, et al. Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr 1998; 67:858-866. (Pubitemid 28196659)